pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,014 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT812Endpoints614BioPharma Dive235onclive165Fierce Biotech81BioSpace79raps32globenewswire health26
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Cytokinetics heart drug scores in closely watched trial
    Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.
    BioPharma Dive · 2mo ago↗ source
  • New Endometrial Targets Beyond HER2
    Interest in endometrial cancer extends well beyond HER2, and the faculty review a growing pipeline of antibody drug conjugates directed at additional targets. Discussion includes why TROPE2 and oth…
    onclive · 2mo ago↗ source
  • Coordinating Care in Multiple Myeloma Across Practice Settings
    onclive · 2mo ago↗ source
← prev
page 36 of 41
next →
fda press21
fda recalls20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • EGFR-Mutated NSCLC: Molecular Reassessment at Disease Progression
    In this case-based segment, Dr. Sands presents a patient with EGFR-mutated metastatic non-small cell lung cancer who has progressed after first-line combination therapy with an EGFR tyrosine kinase…
    onclive · 2mo ago↗ source
  • New Understandings of Treatments, End Points, and Disease Biology Expand MCL Horizons
    Lore Gruenbaum, PhD, discusses the direction mantle cell lymphoma is headed in addition to other critical areas of unmet needs.
    onclive · 2mo ago↗ source
  • Cytokinetics succeeds where Bristol Myers failed in heart muscle disease
    Cytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial for another form of the disease. The…
    Endpoints · 2mo ago↗ source
  • Cytospire hauls in $83M for a new type of T cell engager
    The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies.
    BioPharma Dive · 2mo ago↗ source
  • Vertex drops mRNA cystic fibrosis program over 'tolerability' issues
    Vertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy after facing challenges similar to those that have troubled other parts of the field in delivering th…
    Endpoints · 2mo ago↗ source
  • FDA search for new CBER head focused on small group of final candidates
    The FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three or four final candidates, according to a person familiar with the matter. The agency ho…
    Endpoints · 2mo ago↗ source
  • Celcuity strengthens case for ASCO-spotlighted breast cancer drug
    The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.
    BioPharma Dive · 2mo ago↗ source
  • Supreme Court restores mifepristone access by mail
    The Supreme Court restored mail ordering of mifepristone, reversing a federal appeals court’s stay. The decision Monday came after makers of the pill asked for an immediate response to a ruling ...
    Endpoints · 2mo ago↗ source
  • Celcuity's breast cancer win; Odyssey plans $205M IPO
    Celcuity’s breast cancer drug wins again: The company said two regimens with its experimental drug gedatolisib succeeded in PIK3CA mutant patients as part of its Phase 3 trial. Last year ...
    Endpoints · 2mo ago↗ source
  • With $97M, Latus pursues a different kind of Huntington’s gene therapy
    The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.
    BioPharma Dive · 2mo ago↗ source
  • Biotech has a new startup model: Small team, big check and Chinese assets
    A new flavor of company is shaking up how biotechs are built. Instead of launching with eye-popping early-stage science or a new platform, there's a surge of startups with small teams, large checks…
    Endpoints · 2mo ago↗ source
  • Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial
    A Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The startup, Windward Bio, has raised a ...
    Endpoints · 2mo ago↗ source
  • UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
    The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.
    BioPharma Dive · 2mo ago↗ source
  • What is your AI drug repurposing strategy missing?
    Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.
    BioPharma Dive · 2mo ago↗ source
  • UCB bets $2B on Candid's T cell engager ambitions
    Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is…
    Endpoints · 2mo ago↗ source
  • Bristol Myers’ pivotal year; Should AI be swinging bigger?; and more
    Welcome back to Endpoints Weekly! The last week of April brought a downpour of news as several pharma companies reported their first-quarter earnings. Max Gelman took a close look at a make-or-brea…
    Endpoints · 2mo ago↗ source
  • Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
    Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.
    BioPharma Dive · 2mo ago↗ source
  • Moderna in talks with FDA over Phase 4 Covid vaccine data
    Moderna said it's working with US regulators to provide post-marketing data on its Covid-19 vaccines that could restore their use to a wider group after FDA leaders narrowed the label for the produ…
    Endpoints · 2mo ago↗ source
  • FDA approves Pfizer and Arvinas' breast cancer drug despite underwhelming data
    The FDA on Friday approved Pfizer and Arvinas' drug vepdegestrant for patients with a certain form of breast cancer. But it’s unclear how many will take it. The drug will be ...
    Endpoints · 2mo ago↗ source
  • Amgen launches late-stage obesity trial in patients who switch from rival drugs
    Amgen is launching three new late-stage trials for its long-acting obesity shot MariTide, including one designed to test the drug in patients switching away from Eli Lilly and Novo Nordisk's blockb…
    Endpoints · 2mo ago↗ source
  • Q&A: Seaport CEO and CSO on learning from Karuna and the future of CNS research
    Seaport Therapeutics began trading as a public company on Friday after executives rang the Nasdaq’s opening bell. Shares rose {$SPTX} more than 20%. With a team largely made up of Karuna Therapeuti…
    Endpoints · 2mo ago↗ source
  • Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
    Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast c…
    BioPharma Dive · 2mo ago↗ source